ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

GSK Gsk Plc

1,553.00
29.50 (1.94%)
2024年7月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Gsk Plc GSK ロンドン Ordinary Share
  前日比 前日比 % 現在値 時刻
29.50 1.94% 1,553.00 00:35:08
始値 安値 高値 終値 前日終値
1,525.00 1,521.50 1,557.50 1,553.00 1,523.50
この銘柄の詳細情報 »
業種
PHARMACEUTICALS & BIOTECHNOLOGY

最新ニュース

日付 時間 ソース タイトル
2024/7/2320:07ALNCNewsGSK announces promising trial data for ViiV Healthcare HIV..
2024/7/1918:36UK RNSGSK PLC Blenrep EMA Filing Acceptance
2024/7/1916:12ALNCNewsGSK drug for multiple myeloma accepted for European..
2024/7/1823:30UK RNSGSK PLC Director/PDMR Shareholding
2024/7/1623:30UK RNSGSK PLC Director/PDMR Shareholding
2024/7/1523:30UK RNSGSK PLC Director/PDMR Shareholding
2024/7/1419:18ALNCNewsGSK moves to new global headquarters in return to central..
2024/7/1223:30UK RNSGSK PLC Director/PDMR Shareholding
2024/7/0821:32ALNCNewsIN THE KNOW: UBS downgrades GSK and hacks share price target
2024/7/0317:22ALNCNewsTOP NEWS: GSK inks licensing deal with CureVac for flu and..
2024/7/0315:00UK RNSGSK PLC GSK and CureVac collaboration restructured
2024/7/0123:00UK RNSGSK PLC Total Voting Rights
2024/6/2903:43ALNCNewsIN BRIEF: GSK reaches settlement over Zantac case in..
2024/6/2901:37UK RNSGSK PLC Statement: Zantac (ranitidine) litigation
2024/6/2416:55ALNCNewsTOP NEWS: GSK hails Omjjara approval in Japan; Jemperli..
2024/6/2415:05UK RNSGSK PLC Omjjara approved in Japan for myelofibrosis
2024/6/2415:00UK RNSGSK PLC EMA validates Jemperli marketing authorisation
2024/6/2123:30UK RNSGSK PLC Director/PDMR Shareholding
2024/6/1223:30UK RNSGSK PLC Director/PDMR Shareholding
2024/6/1117:32ALNCNewsTOP NEWS: GSK takes first steps to appeal Zantac ruling in..
2024/6/1115:00UK RNSGSK PLC Statement: Zantac (ranitidine) litigation
2024/6/1103:00ALNCNewsTOP NEWS: GSK welcomes dismissal of Zantac case in Illinois
2024/6/1102:27UK RNSGSK PLC Statement: Zantac (ranitidine) litigation
2024/6/1016:39ALNCNewsGSK gets FDA approval for Arexvy vax in 50-59 year olds at..
2024/6/1015:00UK RNSGSK PLC FDA approves Arexvy for adults 50-59 at risk
2024/6/0323:00UK RNSGSK PLC Total Voting Rights
2024/6/0322:01ALNCNewsGSK immunotherapy bowel cancer drug works for 100% of..
2024/6/0321:03UK RNSGSK PLC Unprecedented results in Jemperli trial continue
2024/6/0317:08ALNCNewsTOP NEWS: GSK vows to appeal adverse Delaware court ruling..
2024/6/0315:05UK RNSGSK PLC ASCO positive Blenrep DREAMM-8 trial results
2024/6/0315:00UK RNSGSK PLC Statement: Zantac (ranitidine) litigation
2024/5/2416:36ALNCNewsTOP NEWS: GSK celebrates Illinois jury verdict in Valadez..
2024/5/2415:00UK RNSGSK PLC Statement: Zantac (ranitidine) litigation
2024/5/2116:49ALNCNewsGSK's depemokimab asthma treatment meets endpoints in latest..
2024/5/2115:00UK RNSGSK PLC Positive phase III asthma results for depemokimab
2024/5/2100:11ALNCNewsIN BRIEF: GSK executive buys GBP20,026 worth shares
2024/5/2023:30UK RNSGSK PLC Director/PDMR Shareholding
2024/5/1717:03ALNCNewsTOP NEWS: GSK sells remaining Haleon stake for GBP1.25..
2024/5/1715:00UK RNSGSK PLC GSK completes sale of shares in Haleon plc
2024/5/1701:13ALNCNewsTOP NEWS: GSK to sell remaining holding in spin-off Haleon
2024/5/1700:42UK RNSGSK PLC GSK announces intention to sell shares in Haleon
2024/5/1423:30UK RNSGSK PLC Director/PDMR Shareholding
2024/5/1323:00UK RNSGSK PLC Block listing Interim Review
2024/5/0902:21UK RNSGSK PLC Result of AGM
2024/5/0900:57UK RNSGSK PLC Board Committee Change
2024/5/0714:00GLOBEBioVersys Announces Expansion of Strategic Collaboration..
2024/5/0323:30UK RNSGSK PLC Director/PDMR Shareholding
2024/5/0123:00UK RNSGSK PLC Total Voting Rights
2024/5/0116:50ALNCNewsTOP NEWS: GSK expects momentum to continue after strong..
2024/5/0115:00UK RNSGSK PLC 1st Quarter Results

最近閲覧した銘柄

Delayed Upgrade Clock